{"preliminary_commentary":{"by_channel":{"x_thread":11,"youtube":3,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05468697\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["belzutifan","palbociclib"]],"indication":"advanced renal cell carcinoma","name":"LITESPARK-024","nct_id":"NCT05468697","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=litespark-024-nct05468697. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive beltuzifan 120 mg orally once per day (QD) and palbociclib 75 mg orally QD in a 28-day schedule (21 days on followed by 7 days off), until progressive disease or discontinuation.","label":"Beltuzifan 120 mg + Palbociclib 75 mg","type":"EXPERIMENTAL"},{"description":"Participants receive beltuzifan 120 mg orally QD and palbociclib 100 mg orally QD in a 28-day schedule (21 days on followed by 7 days off), until progressive disease or discontinuation.","label":"Beltuzifan 120 mg + Palbociclib 100 mg","type":"EXPERIMENTAL"},{"description":"Participants receive beltuzifan 120 mg orally QD and palbociclib 125 mg orally QD in a 28-day schedule (21 days on followed by 7 days off), until progressive disease or discontinuation.","label":"Beltuzifan 120 mg + Palbociclib 125 mg","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-12-22","type":"ESTIMATED"},"conditions":["Renal Cell Carcinoma"],"enrollment":{"count":60,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Belzutifan","otherNames":["WELIREG™","MK-6482","PT2977"],"type":"DRUG"},{"name":"Palbociclib","otherNames":["IBRANCE®","PD 0332991"],"type":"DRUG"}],"last_update":"2026-10-27","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Multicenter, Open-label, Randomized, Phase 1/2 Study of Belzutifan in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-12-22","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of Participants Who Experience at Least One Dose-limiting Toxicity (DLT)","timeFrame":"Up to approximately 28 days"},{"measure":"Number of Participants Who Experience at Least One Adverse Event (AE)","timeFrame":"Up to approximately 4 years"},{"measure":"Number of Participants Who Discontinue Study Treatment Due to an AE","timeFrame":"Up to approximately 4 years"}],"references":[{"citation":"Meiman D, Skaar TC, Shugg T, Quinney SK. Physiologically Based Pharmacokinetic Model to Assess the Drug-Drug-Gene Interaction Potential of Belzutifan in Combination With Cyclin-Dependent Kinase 4/6 Inhibitors. JCO Precis Oncol. 2025 Jul;9:e2500153. doi: 10.1200/PO-25-00153. Epub 2025 Jul 25.","pmid":"40712111","type":"DERIVED"}],"start_date":{"date":"2022-08-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)","url":"https://clinicaltrials.gov/study/NCT05468697"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/litespark-024-nct05468697"}